Bictegravir vs Dolutegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir · Biktarvy
Marketed by Gilead Sciences
NCT02607956 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.
Next expected readout: December 2026 · NCT06830668 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)
Result source: NCT03110380
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Marketed by GlaxoSmithKline and partners
NCT01263015 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)
Result source: NCT01263015
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bictegravir | Dolutegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 92.4% vs 93%vs ABC/DTG/3TCNCT026079305 other results
| 88% vs 85%vs RTGNCT0122782412 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0.4% vs 1.1%vs DTG + F/TAFNCT03110380 | —Not posted · NCT01837277 |
| CD4 count, change (week 48) | 278 vs 289vs DTG + F/TAFNCT026079566 other results
| 163 vs 174−11 vs placeboNCT0156889244 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Bictegravir
- 92.4% vs 93%vs ABC/DTG/3TCNCT02607930
5 other results
- 81.5% vs 84.1% NCT02607930
- 87.9% vs 89.8% NCT02607930
- 93.3% vs 91.1% NCT03110380
- 96.9% vs 93.9% NCT02397694
- 96.9% vs 90.9% NCT02397694
- Dolutegravir
- 88% vs 85%vs RTGNCT01227824
12 other results
- 90% vs 83% NCT01449929
- 88% vs 81% NCT01263015
- 90% vs 93% NCT02831673
- 93% vs 94% NCT02831764
- 71% vs 63% NCT01263015
- 77% vs 70% NCT01263015
- 79% vs 83% NCT02831673
- 84% vs 84% NCT02831764
- 84% vs 89% NCT02831673
- 88% vs 90% NCT02831764
- 92% vs 93% NCT02831673
- 94% vs 94% NCT02831764
HIV-1 RNA 50 copies/mL or more (week 48)
- Bictegravir
- 0.4% vs 1.1%vs DTG + F/TAFNCT03110380
- Dolutegravir
- —Not posted · NCT01837277
CD4 count, change (week 48)
- Bictegravir
- 278 vs 289vs DTG + F/TAFNCT02607956
6 other results
- 299 vs 317 NCT02607930
- 237 vs 281 NCT02607956
- 287 vs 288 NCT02607930
- 180 vs 201 NCT02607956
- 235 vs 228 NCT02607930
- 18 vs 36 NCT03110380
- Dolutegravir
- 163 vs 174−11 vs placeboNCT01568892
44 other results
- 170 vs 146 NCT01568892
- 115 vs 156 NCT01568892
- 90.5 vs 125.5 NCT01568892
- 48 vs 135.5 NCT01568892
- 39 vs 117 NCT01568892
- 292.2 vs 286.2 NCT01227824
- 281.3 vs 292.9 NCT01227824
- 247.8 vs 278.6 NCT01227824
- 247.8 vs 264.2 NCT01227824
- 238.9 vs 257.5 NCT01227824
- 248.8 vs 230.7 NCT01910402
- 224.1 vs 239.8 NCT01227824
- 230.7 vs 191.4 NCT01910402
- 223.4 vs 241.3 NCT01227824
- 199.3 vs 204.2 NCT01227824
- 200.6 vs 163 NCT01910402
- 378.5 vs 331.6 NCT01263015
- 379.5 vs 333.3 NCT01263015
- 377.9 vs 327.2 NCT01263015
- 347 vs 311 NCT01263015
- 349.3 vs 298.9 NCT01263015
- 322.6 vs 286 NCT01263015
- 315.2 vs 272.1 NCT01263015
- 306.1 vs 269.6 NCT01263015
- 271.3 vs 235.3 NCT01263015
- 267.5 vs 209.5 NCT01263015
- 265.5 vs 216.2 NCT01263015
- 250.5 vs 208.1 NCT01263015
- 216.9 vs 177.8 NCT01263015
- 301.8 vs 303.2 NCT02831673
- 301.7 vs 296.6 NCT02831764
- 264.7 vs 253.8 NCT02831673
- 272 vs 264.6 NCT02831764
- 265 vs 230 NCT02259127
- 311 vs 230 NCT02259127
- 228 vs 230 NCT02259127
- 222.2 vs 217.7 NCT02831673
- 225.7 vs 217.2 NCT02831764
- 192.2 vs 175.1 NCT02831673
- 188.8 vs 163.2 NCT02831764
- 72 vs 230 NCT02259127
- 39 vs 28 NCT02263326
- 88 vs 75 NCT03991013
- 111 vs 101 NCT03851588
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Bictegravir: 7 of 7 rows · Dolutegravir: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bictegravir Rows use multiple source trials | Dolutegravir Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 382.4211 cells/uL @ 48wka,b,c NCT04530630 · Phase 4 · registry result, not featured evidence | 110 cells/uL @ 48wk50 mg BIDa,b,c NCT01328041 · Phase 3 |
| HIV-1 RNA absolute change · log Induction | -3.03 vs -3.15 DTG + F/TAF log @ 12wkd,b NCT02397694 · Phase 2 · registry result, not featured evidence · combination | -3.01 vs -2.85 EFV/TDF/FTC log @ 12wk50 mg plus 600/300 mg once dailyd,b NCT01263015 · Phase 3 · combination · HIV · phase 3 4 other source trials-2.908 vs -2.918 RTG log @ 12wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 -2.88 vs -2.61 DRV + RTV log @ 12wk50 mg once daily NCT01449929 · Phase 3 -2.756 vs -2.541 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 12wk NCT01910402 · Phase 3 · registry result, not featured evidence -1.54 vs -2.02 placebo log @ 12wk50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log Maintenance | -3.06 vs -3.11 DTG + F/TAF log @ 144wke,c NCT02607956 · Phase 3 · HIV · phase 3 1 other source trial-3.11 vs -3.1 ABC/DTG/3TC log @ 144wk NCT02607930 · Phase 3 · HIV · phase 3 | -3.02 vs -3.04 EFV/TDF/FTC log @ 144wk50 mg plus 600/300 mg once dailye,c NCT01263015 · Phase 3 · combination · HIV · phase 3 |
| Dropout rate | 18.7%f NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results17.1%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 7.4%B/F/TAF NCT03110380 · Phase 3 —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination 5% NCT04530630 · Phase 4 · registry result, not featured evidence 11.9% NCT05405751 · Phase 4 · registry result, not featured evidence — NCT03656783 · Phase 3 · registry result, not featured evidence 4.6%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 20%50 mg NCT02275065 · Phase 1 · registry result, not featured evidence 20%100 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02275065 · Phase 1 · registry result, not featured evidence 20%5 mg NCT02275065 · Phase 1 · registry result, not featured evidence | 17.4%50 mg plus 600/300 mg once dailyg NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results26%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 13.6%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 31.1%50 mg BID NCT01328041 · Phase 3 8.5% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 10.7% NCT04585737 · Phase 4 · registry result, not featured evidence 25.6%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 13.1%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 16.2%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 11.4%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 7.8%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 4.7%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence 0%50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 0%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 0%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 23.9% NCT01837277 · Phase 2/3 · registry result, not featured evidence 0%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 1.5% NCT03991013 · Phase 2 · registry result, not featured evidence 3.8% NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 1.2%f NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results0%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 1.1%B/F/TAF NCT03110380 · Phase 3 —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination — NCT04530630 · Phase 4 · registry result, not featured evidence — NCT05405751 · Phase 4 · registry result, not featured evidence — NCT03656783 · Phase 3 · registry result, not featured evidence 1.5%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination —50 mg NCT02275065 · Phase 1 · registry result, not featured evidence —100 mg NCT02275065 · Phase 1 · registry result, not featured evidence —25 mg NCT02275065 · Phase 1 · registry result, not featured evidence —5 mg NCT02275065 · Phase 1 · registry result, not featured evidence | 3.1%50 mg plus 600/300 mg once dailyg NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results2.9%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 2.1%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 3.8%50 mg BID NCT01328041 · Phase 3 — NCT04880395 · Phase 4 · registry result, not featured evidence · combination — NCT04585737 · Phase 4 · registry result, not featured evidence —Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination —Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination —Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination —Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination — NCT02263326 · Phase 3 · registry result, not featured evidence · combination 7.7%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence — NCT01837277 · Phase 2/3 · registry result, not featured evidence —50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence —50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence — NCT03991013 · Phase 2 · registry result, not featured evidence — NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 20%f NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results14%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 7.5%B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF NCT03110380 · Phase 3 12.7%Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 9.6%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 9.5%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination 5% NCT04530630 · Phase 4 · registry result, not featured evidence 4% NCT05405751 · Phase 4 · registry result, not featured evidence 0% NCT03656783 · Phase 3 · registry result, not featured evidence —BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination 6.2%BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 0%50 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%100 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02275065 · Phase 1 · registry result, not featured evidence | 15.7%50 mg plus 600/300 mg once dailyg NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results10%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 6.2%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg once daily NCT01449929 · Phase 3 14.9%50 mg once daily NCT01449929 · Phase 3 3.3%50 mg once daily NCT01449929 · Phase 3 25.1%50 mg BID NCT01328041 · Phase 3 9.9% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 8.1% NCT04585737 · Phase 4 · registry result, not featured evidence 7.7%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 8.2%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence 8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 2.1%DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 10.4%DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination 3.6%DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 10.8%DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 18%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 18.1%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 35.7%50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 26.2%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 10%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 14.9%Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 6.1%Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 9.8% NCT01837277 · Phase 2/3 · registry result, not featured evidence 6.9%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 3.1% NCT03991013 · Phase 2 · registry result, not featured evidence 0% NCT03851588 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence 7.1%Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 12 more resultsdiarrhoea 17.2% upper respiratory tract infection 14.6% headache 14% NCT02607930 · Phase 3 · HIV · phase 3 loose stool/ diarrhea 25% NCT04530630 · Phase 4 · registry result, not featured evidence shortness of breath 8% NCT03656783 · Phase 3 · registry result, not featured evidence diarrhoea 13.8% upper respiratory tract infection 10.8% headache 9.2% NCT02397694 · Phase 2 · registry result, not featured evidence · combination 50 mg fatigue 25% (placebo 0%) papule 25% (placebo 0%) arthropod bite 0% (placebo 0%) NCT02275065 · Phase 1 · registry result, not featured evidence 100 mg arthropod bite 25% (placebo 0%) diarrhoea 25% (placebo 0%) headache 25% (placebo 25%) NCT02275065 · Phase 1 · registry result, not featured evidence 25 mg headache 25% (placebo 25%) arthropod bite 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) NCT02275065 · Phase 1 · registry result, not featured evidence 5 mg blood creatine phosphokinase increased 25% (placebo 0%) diarrhoea 25% (placebo 0%) headache 25% (placebo 25%) NCT02275065 · Phase 1 · registry result, not featured evidence | 50 mg plus 600/300 mg once dailyg diarrhoea 22.7% nasopharyngitis 20.8% insomnia 17.9% NCT01263015 · Phase 3 · combination · HIV · phase 3 show 31 more results50 mg Once a Day upper respiratory tract infection 8% syphilis 7.1% viral upper respiratory tract infection 7.1% NCT01227824 · Phase 3 · HIV · phase 3 50 mg once daily viral upper respiratory tract infection 4.1% gastroenteritis 2.4% asthenia 1.6% NCT01449929 · Phase 3 insomnia/nightmares 3.9% alopecia 2% itching/rash/prurigo 2% NCT04880395 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 8.7% headache 8.1% urinary tract infection 6% NCT01910402 · Phase 3 · registry result, not featured evidence nausea 18.5% headache 11.7% diarrhoea 9.3% NCT01910402 · Phase 3 · registry result, not featured evidence covid-19 6.9% suspected covid-19 3.4% headache 3% NCT02831673 · Phase 3 · registry result, not featured evidence · combination headache 14.3% diarrhoea 14% nasopharyngitis 13.8% NCT02831673 · Phase 3 · registry result, not featured evidence · combination covid-19 6% syphilis 4% respiratory tract infection viral 3.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.6% upper respiratory tract infection 13.1% nasopharyngitis 12.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 83.9% blood creatinine increased 78.3% haemoglobin decreased 3.7% NCT03048422 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 89.8% blood creatinine increased 83.3% haemoglobin decreased 9.3% NCT03048422 · Phase 3 · registry result, not featured evidence · combination grade 3 bilirubinemia 0% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 50 mg OD headache 53.8% upper respiratory tract infection 38.5% diarrhoea 30.8% NCT01499199 · Phase 3 · registry result, not featured evidence 50mg BID diarrhoea 21.4% (placebo 12.5%) headache 21.4% (placebo 6.3%) lymphadenopathy 21.4% (placebo 0%) NCT01568892 · Phase 3 · registry result, not featured evidence cns disturbances 0% NCT01837277 · Phase 2/3 · registry result, not featured evidence 50 mg BID abnormal loss of weight 10% blood pressure increased 10% headache 10% NCT05630872 · Phase 2 · registry result, not featured evidence acute psychosis 1.5% (placebo 0%) incident pulmonary tuberculosis 1.5% (placebo 0%) acute kidney injury 0% (placebo 3.1%) NCT03991013 · Phase 2 · registry result, not featured evidence insomnia 5.7% (placebo 0%) NCT03851588 · Phase 2 · registry result, not featured evidence haemoglobin decreased 33.3% alanine aminotransferase increased 16.7% aspartate aminotransferase increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 50% alanine aminotransferase increased 16.7% blood bilirubin increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 83.3% neutrophil count decreased 50% acne infantile 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 42.9% blood bilirubin increased 35.7% dermatitis diaper 21.4% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 56.3% neutrophil count decreased 31.3% blood bilirubin increased 25% NCT05406583 · Phase 1 · registry result, not featured evidence hypokalaemia 71.4% (placebo 71.4%) hypoglycaemia 42.9% (placebo 71.4%) vivid dreams 28.6% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence hypokalaemia 62.5% (placebo 71.4%) cold 25% (placebo 14.3%) bloating 12.5% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 2 versus Phase 3.
- ePopulation context differs: baseline_threshold differs (hiv_viral_load>=500 versus hiv_viral_load>=1000).
- fPopulation comparability has not been reviewed for 13 of these studies.
- gPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bictegravir
show 2 more results
show 5 more results
show 2 more results
show 2 more results
show 4 more results
show 2 more results
Dolutegravir
show 3 more results
show 3 more results
show 1 more result
+ 77 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Dolutegravir's landscape